Doxycycline

Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1].

Research Areas >> Infection

Signaling Pathways >> Metabolic Enzyme/Protease >> MMP

Doxycycline affects growth of glioma cells only under high concentrations[2]. Doxycycline decreases MT-CO1 protein content with concentrations of 1 µg/mL and higher in SVG cells[2]. Cell Proliferation Assay[2] Cell Line: LNT-229, G55, and U343 glioma cells Concentration: 0.01, 0.1, 1, or 10 µg/mL Incubation Time: 4 days Result: Affected growth of glioma cells only under high concentrations. Western Blot Analysis[2] Cell Line: SVG cells Concentration: 0.01, 0.1, 1, or 10 µg/mL Incubation Time: 24 hours Result: Decreaseed MT-CO1 protein content with concentrations of 1 µg/mL and higher.

Doxycycline (oral; 200 or 800 mg/kg/day; for 3 months) reduces active MMP-9 in untreated HT mice in a dose-dependent manner[1]. Animal Model: 6-month-old female Heterozygous Col3a1-deficient (HT) mice[1] Dosage: 200 or 800 mg/kg Administration: Oral; per day; for 3 months Result: Reduced active MMP-9 in a dose-dependent manner.

[1]. Briest W, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.

[2]. Luger AL, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5).

MOLECULAR FORMULA :

C22-H24-N2-O8

MOLECULAR WEIGHT :

444.48

WISWESSER LINE NOTATION :

L E6 C666 BV FV CU GUTTT&J DQ GVZ HQ IN1&1 KQ MQ M1 RQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Human - woman

DOSE/DURATION :

68 mg/kg/24D-I

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

>2 gm/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

378 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - rat

DOSE/DURATION :

228 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

1870 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intraperitoneal

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

410 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Rodent - mouse

DOSE/DURATION :

241 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Oral

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

>500 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :

Intravenous

SPECIES OBSERVED :

Mammal - dog

DOSE/DURATION :

>100 mg/kg

TOXIC EFFECTS :

Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :

TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :

Oral

DOSE :

750 mg/kg

SEX/DURATION :

female 2 day(s) after conception

TOXIC EFFECTS :

Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

MUTATION DATA

TYPE OF TEST :

DNA inhibition

TEST SYSTEM :

Human Lymphocyte

DOSE/DURATION :

3750 ug/L

REFERENCE :

BCPHBM British Journal of Clinical Pharmacology. (Blackwell Scientific Pub. Ltd., POB 88, Oxford, UK) V.1- 1974- Volume(issue)/page/year: 16,127,1983 *** REVIEWS *** TOXICOLOGY REVIEW PBPSDY Pharmacological and Biochemical Properties of Drug Substances. (American Pharmaceutical Assoc., 2215 Constitution Ave., NW, Washington, DC 20037) V.1- 1977- Volume(issue)/page/year: 2,305,1979 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84744 No. of Facilities: 641 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 1281 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84744 No. of Facilities: 450 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 22055 (estimated) No. of Female Employees: 18813 (estimated)